News and Trends 22 Aug 2022
Santhera and ReveraGen announce first patient with Becker muscular dystrophy dosed in FDA-funded pilot study
The first patient has been dosed in a phase 2 pilot study looking at a treatment for muscular dystrophy. Santhera Pharmaceuticals and ReveraGen BioPharma made the announcement that vamorolone is…